Brent Pfeiffenberger was appointed Director of Corbus Pharmaceuticals Holdings, Inc. As of November 6, 2026, Corbus Pharmaceuticals Holdings, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 7, 2026 to May 14, 2026, naming 1 appointment (Form 8-K, May 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Corbus Pharmaceuticals Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Corbus Pharmaceuticals Holdings, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-07 to 2026-05-14. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Corbus Pharmaceuticals Holdings, Inc. files it.
Also on the record for Corbus Pharmaceuticals Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 2, 2026 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | 7.76% of the class | 5%+ stakes | Source |
| October 29, 2026 | Stake report, Schedule 13G/A, by Aberdeen Group plc | — | 5%+ stakes | Source |
| September 30, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Citadel Securities LLC | 1.1% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.9% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Octagon Capital Advisors LP | — | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Octagon Capital Advisors LP | 5.4% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13G, by Aberdeen Group plc | 7.53% of the class | 5%+ stakes | Source |
| December 15, 2025 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | 13.36% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Cormorant Asset Management, LP | 12.82% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by Kenneth Griffin | 5.3% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.89% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Corbus Pharmaceuticals Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Corbus Pharmaceuticals Holdings, Inc. and the records around it.
Corbus Pharmaceuticals Holdings, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Dianthus Therapeutics, Inc. /DE/ (May 2026)
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026), Bright Minds Biosciences Inc. (Aug 2026)
Watch Corbus Pharmaceuticals Holdings, Inc.
Get an email when Corbus Pharmaceuticals Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Corbus Pharmaceuticals Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Corbus Pharmaceuticals Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Corbus Pharmaceuticals Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-14 | In | Director | 8-K, 2026-05-14 | ||
| 2026-04-07 | Reported | not named in the filing | 8-K, 2026-04-07 |
Who leads Corbus Pharmaceuticals Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Brent Pfeiffenberger, appointed (filed 2026-05-14).
New leaders reset buying decisions — get the Full Report on Corbus Pharmaceuticals Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Corbus Pharmaceuticals Holdings, Inc., with the record behind each one.
Find candidates like Director at Corbus Pharmaceuticals Holdings, Inc.Every change, in the filing's words
Appointed: Brent Pfeiffenberger, Director
Director Appointment On May 13, 2026, the board of directors (the "Board") of Corbus Pharmaceuticals Holdings, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members.
- Dr. Pfeiffenberger will hold this position until the next annual meeting of the Company's stockholders or until his successor is elected and qualified, subject to his earlier resignation or removal.
- The Board has determined that Dr. Pfeiffenberger is independent within the meaning of the Nasdaq Listing Rules and Rule 10A-3 under the Securities Exchange Act of 1934, as amended.
- Dr. Pfeiffenberger has been the President and Chief Executive Officer and a member of the board of directors of Century Therapeutics, Inc. (NASDAQ: IPSC) since December 2023, and was appointed chairman of the board of directors in August 2025.
- Dr. Pfeiffenberger previously served as Chief Operating Officer of Neogene Therapeutics Inc., a clinical-stage biotechnology company, from May 2021 until December 2023.
- Prior to this, Dr. Pfeiffenberger held various positions at Bristol-Myers Squibb Company, or Bristol-Myers, a global biopharmaceutical company, including Senior Vice President and Head of U.S. Oncology from October 2019 until May 2021; Co-Lead of Worldwide Commercial Oncology from July 2018 until October 2019; General Manager for Australia and New Zealand from March 2016 until June 2018; and several additional leadership and managerial positions within Bristol-Myers prior to this.
Reported
On April 1, 2026, Corbus Pharmaceuticals Holdings, Inc. (the "Company") was notified by Dominic Smethurst, the Company's Chief Medical Officer, of his resignation, effective June 30, 2026.
Tools for this story
Each opens in a new tab, filled in for Corbus Pharmaceuticals Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.